妊娠期子宫肌瘤的自然史:美国国家儿童健康与人类发育研究所胎儿生长研究-单胎队列
这项前瞻性队列研究纳入2774名孕妇,在孕10-41周进行最多6次产科超声,记录肌瘤数量和3个最大肌瘤的体积。总体肌瘤总容积平均每周下降1.0%(95%CI -1.9%至-0.2%),但变化轨迹因初始体积和母体特征而异。
要点
- 孕期9.6%(266/2774)妇女超声可视到肌瘤,非西班牙裔黑人妇女占14%(106/770)。
- 肌瘤总容积平均每周下降1.0%(95%CI -1.9%至-0.2%)。
- 初始小体积者总容积平均每周增加2.0%(95%CI -0.3%至4.5%),大体积者每周下降2.2%(95%CI -3.4%至-1.0%)。
核心结论
- 妊娠期肌瘤总容积平均下降,但汇总所有肌瘤掩盖了按初始总容积和母体特征划分的显著异质性。
- 研究结果可为临床医生预测产科患者肌瘤变化提供参考。
研究设计与样本
- 前瞻性队列研究,纳入2774名孕妇,来自12个临床中心,种族多样(27%非西班牙裔白人、28%非西班牙裔黑人、29%西班牙裔、17%亚裔/太平洋岛民)。
- 孕妇在孕10-41周接受最多6次产科超声,超声技师记录每次访视的肌瘤数量和3个最大肌瘤的体积。
- 采用广义线性混合模型估计肌瘤数量和总容积的轨迹,并按首次可视总容积分层(相当于直径<1 cm为小、1至<3 cm为中、≥3 cm为大)。
- 检验轨迹与种族/民族、年龄(<26、26-30、31-34、≥35岁)、体重指数(<25、25-29.9、≥30 kg/m2)、既往流产、产次和胎儿性别的交互作用,并调整首次可视总容积。
主要发现
- 总体9.6%(266/2774)妇女孕期任一时刻可视到肌瘤,其中非西班牙裔白人9%(67/745)、非西班牙裔黑人14%(106/770)、西班牙裔6%(47/794)、亚裔或太平洋岛民10%(46/465)。
- 肌瘤总容积平均每周下降1.0%(95%CI -1.9%至-0.2%),起始总容积存在变异。
- 首次可视小体积者总容积平均每周增加2.0%(95%CI -0.3%至4.5%),中体积者每周下降0.5%(95%CI -2.0%至1.0%),大体积者每周下降2.2%(95%CI -3.4%至-1.0%)。
- 非西班牙裔黑人妇女总肌瘤容积平均每周变化-2.6%,非西班牙裔白人0.1%,西班牙裔0.5%,亚裔/太平洋岛民0.9%,黑人妇女下降更多。
- 可视肌瘤数量平均每周下降1.2%(95%CI -1.9%至-0.5%),未见人口学特征间的显著变异。
临床怎么用
- 原文未据此给出推荐,仅指出研究结果可能有助于临床医生预测产科患者肌瘤的变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the natural history of fibroids in pregnancy in a racially diverse cohort and explore whether fibroid changes were associated with participant characteristics. DESIGN: Prospective cohort study. SETTING: Twelve clinical sites. PATIENT(S): Pregnant women (n = 2774; 27% non-Hispanic White, 28% non-Hispanic Black, 29% Hispanic, 17% Asian/Pacific Islander) who had up to 6 obstetric ultrasounds in gestational weeks 10-41. INTERVENTION(S): Sonographers recorded fibroid number and volume of the 3 largest fibroids at each visit. Generalized linear mixed models estimated the trajectories of fibroid number and total volume (overall and stratified by total volume at first visualization: equivalent to a fibroid of <1 cm [small], 1 to <3 cm [medium], or ≥3 cm [large] in diameter). We tested the interactions between the trajectories and race/ethnicity, age (<26, 26-30, 31-34, and ≥35 years), body mass index (<25, 25-29.9, and ≥30 kg/m2), previous miscarriage, parity, and fetal sex, adjusted for total volume at first visualization. MAIN OUTCOME MEASURE(S): Average change in total fibroid volume during pregnancy. RESULT(S): Overall, 9.6% (266/2,774) of women had a visualized fibroid at any time during pregnancy, including 9% (67/745) of non-Hispanic White women, 14% (106/770) of non-Hispanic Black women, 6% (47/794) of Hispanic women, and 10% (46/465) of Asian or Pacific Islander women. The mean total fibroid volume decreased by 1.0% (95% confidence interval [CI], -1.9%, -0.2%) per week, with a variation in starting total volume. On average, the total volume increased by 2.0% (95% CI, -0.3%, 4.5%) per week among women with small volume; decreased by 0.5% (95% CI, -2.0%, 1.0%) per week among women with medium volume; and decreased by 2.2% (95% CI, -3.4%, -1.0%) per week among women with large volume at first visualization. The volume change also varied by race or ethnicity, parity, age, and miscarriage history. For example, non-Hispanic Black women's total fibroid volume decreased more than those of non-Hispanic White, Hispanic and Asian/Pacific Islander women (-2.6%, 0.1%, 0.5%, and 0.9% average change per week, respectively). The visualized fibroid number declined on an average by 1.2% per week (95% CI, -1.9%, -0.5%) without significant variation by demographic characteristics. CONCLUSION(S): The total fibroid volume declined on average throughout pregnancy. However, summarizing across all fibroids disguises substantial heterogeneity by starting total fibroid volume and maternal characteristics. The findings may be a useful reference for clinicians to anticipate how fibroids may change in obstetric patients. CLINICAL TRIAL REGISTRATION NUMBER: NCT00912132.
引用
- Mitro SD, Peddada S, Chen Z, et al. Natural history of fibroids in pregnancy: National Institute of Child Health and Human Development Fetal Growth Studies - Singletons cohort. Fertil Steril. 2022. PMID: 35981916. doi:10.1016/j.fertnstert.2022.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。